cslbehring.se
Von Willebrand Disease
http://www.cslbehring.se/s1/cs/bese/1252899238848/content/1252899231141/content.htm
Include All CSL Behring Country Sites. Physicians & Health Care Professionals. Patients & Families. Haemolytic disease of the newborn. Congenital Factor XIII Deficiency. People with von Willebrand disease. VWD) have a problem with one of the clotting factors in the blood; this particular clotting factor is known as von Willebrand factor. In people unaffected by von Willebrand disease, this clotting factor helps platelets stick to the wall of the damaged blood vessel and assists the glue-like clotting.
cslbehring.com
Immunoglobulin, IVIg & SCIg | CSL Behring
http://www.cslbehring.com/s1/cs/enco/1255923358055/page/1255923357721/TabsLandingPage.htm
All CSL Behring Web Sites. Health, Safety & Environment. Quality & Safety. CSL Research & Development. Other Areas of Business. CSL Behring offers one of the world's most comprehensive portfolios of safe, high quality, technically advanced immunoglobulin (Ig) products designed to offer patients the convenience, choice, and ease of administration that they seek. The body's immune system can then work more effectively. CSL Behring Immunoglobulin Products. The CSL Behring product portfolio includes key immu...
cslbehring.se
Physicians & Health Care Professionals
http://www.cslbehring.se/s1/cs/bese/1164719155492/content/1164719155034/content.htm
Include All CSL Behring Country Sites. Physicians & Health Care Professionals. CSL Behring Nordic VW Scholarship. Patients & Families. Physicians and Health Care Professionals. Physicians and Health-care Professionals. Welcome to our section for physicians and health-care professionals. Here you will find information about our medicinal products as well as access to scientific literature, and links to further relevant information. The Patient and Families. If you have any questions.
cslbehring.se
Privacy Policy
http://www.cslbehring.se/s1/cs/bese/1160484846607/content/1160484846331/content.htm
Include All CSL Behring Country Sites. Physicians & Health Care Professionals. Patients & Families. Thank you for visiting www.cslbehring.se. Information Collected from You. How to Contact Us. Information Collected from You. Only when you specifically request it will the information that we collect be used to respond to your questions, or to fulfill e-mail messaging programs, and notify visitors about new content or services on our Web sites. The domain and host from which you access the Internet. You ma...
cslbehring.se
CSL Behring
http://www.cslbehring.se/s1/cs/bese/1160484846586/page/1252899180566/HomepageTemplate.htm
Include All CSL Behring Country Sites. Physicians & Health Care Professionals. Patients & Families. CSL Behring is committed to improving the quality of life for patients with rare and serious diseases. The company develops, manufactures and markets a range of products for the following therapy areas:. Products for the treatment of Congenital FXIII Deficiency, Congenital Fibrinogen Deficiency, Haemophilia, Rapid Warfarin Reversal and von Willebrand Disease. Congenital Factor XIII Deficiency.
cslbehring.com
CSL Behring: Global Life Saving Biotherapies, Plasma Protein Biotherapeutics
http://www.cslbehring.com/s1/cs/enco/1151443990667/content/1151443991017/home.htm
All CSL Behring Web Sites. Health, Safety & Environment. Quality & Safety. CSL Research & Development. Other Areas of Business. CSL Behring develops, manufactures and markets protein based therapies, including:. Hereditary Angioedema (HAE) Therapies. Paul Perreault Talks About Innovation. Paul Perreault on Bloomberg News: "If you're not innovating in this rare disease space, you're planning your exit.". Tim’s Story: Outdoor Adventurer Remains Active Despite Hemophilia.
csl.com.au
CSL completes Novartis influenza vaccine business acquisition
http://www.csl.com.au/Investors/CSL-Completes-Novartis-Influenza-Vaccine-Business-Acquisition.htm
CSL Plasma Services (Germany). R&D and Operational Briefings. CSL completes Novartis influenza vaccine business acquisition. CSL completes Novartis influenza vaccine business acquisition. CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. As foreshadowed in CSL’s release to the Australian Securities Exchange on 31 July. For further information, please contact:.
csl.com.au
CSL - Financial Reports
http://www.csl.com.au/investors/financial-reports.htm
CSL Plasma Services (Germany). R&D and Operational Briefings. Half Year Report 2015-2016. As CSL reaches a remarkable milestone this year, marking 100 years of developing and delivering innovations to help patients live life to the fullest, I am pleased to report an exceptional first half year result. For the six months ended 31 December 2015, CSL reported net profit after tax of US$719 million, an increase of US$27 million (4% on a reported basis) on the same period last year. Half Year Report 2015-2016.
cslbehring.com
CSL Behring: Professor Heimburger Award, Global Research Grant Coagulation
http://www.cslbehring.com/products/bleeding-disorders/professor-heimburger-award.htm
All CSL Behring Web Sites. Health, Safety & Environment. Quality & Safety. CSL Research & Development. Other Areas of Business. CSL Behring Prof. Heimburger Award. Global Research Grant Coagulation. Award Winners (2008 2015). For inquiries regarding applications, policy and procedures information, please contact:. T: 49 6421 394191. E-mail: heimburger.award@cslbehring.com. Prof Heimburger Award 2016:. Professor Dr. Norbert Heimburger. Due to his determination and his constant interaction with leading hem...